People · Operator
Named in public records as an officer, director or promoter · active 2021–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Shoreline Biosciences, Inc. | — | Biotechnology | Series D+ | $186.0M | $3.7B | 2021 |
Christopher S. Fuglesang at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher S. Fuglesang on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| KLEANTHIS G. XANTHOPOULOS | 1 | 2 |
| Vanessa S. Jacoby | 1 | 1 |
| William S. Sandborn | 1 | 1 |
| Kimberly S. Manhard | 1 | 1 |
| Scott S. Forrest | 1 | 1 |
| Fan S. Yu | 1 | 1 |
| Marios G. Fotiadis | 1 | 1 |
| Steven G. Holtzman | 1 | 1 |
| Dan S. Kaufman | 1 | 1 |
| Kleanthis G. Xanthopoulos, Ph.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.